Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For the past year now its been saying it was stuck at around .10+ to .08+ ish, now the data has changed on the websites and Firstrade, if you use that.
Back in 2/24/21 it hit 58.80 before the split.
Did anyone else notice the price jump up to 9.73 on 4/20/22? well before the split? the numbers are not adding up. its like the stock just locked or had an overlay. My data is showing some crazy information right now.
WOW!!! I did not see it bouncing back like it did today!!
It closed at close to $ 4 yesterday and is sitting at $ 5 right now.
Fantastic!! Jim
There are no formal limits on how many times a company can perform reverse stock splits, but there are practical limits. The company must maintain at least 500,000 outstanding shares to stay listed on the NASDAQ and 200,000 to stay on the NYSE. Each reverse split reduces the number of shares a company has. (Two cents: when you talk about anything someone is always there to pick it up or put it down.)
No, I had bought in at ten cents before the end of the year and had felt forty cents was a good sell point, as February usually gets up between forty to sixty cents, so I set my order and figured it was good to go.
They then do the split, and suddenly my order is somehow locked up, with a price well above forty cents but shares that cannot be sold due to being held up.
I would have thought that they either would have canceled the order due to the split or executed the order since it got above forty cents.
I have been "churning" this each February since circa 2015 and it did a nice return each year by dumping in fall, buying back in before new year to catch the February up swing. The split screwed all of that up.
Thanks and take care, Jim
No, sorry no idea what is going on on your side there. Maybe reach out to support see what they have to say.
You were trying to exit this disaster?
I had an open order to sell at 40 cents since December and since the split Etrade says that it is too late to execute the sell order.
Does anyone else have this issue or experience with it?
I am trying to sell and while it no longer recognizes the order as open so as to be able to cancel it, it also will not allow me to cancel it as it is past being able to... ???
I cannot figure out why when it was over 40 cents it didn't execute, but beyond that, now has me locked in.
Please advise if anyone else has this issue and if you resolved it, how.
Thank You, Jim
Soon back under a dollar, increase shares to offer for funding, further diluting long-term investors until their shares are worthless. I guess I'll just walk away from this for there's nothing here anymore.
Never really seen RS to work the way business proposes it to shareholders in OTCM, instead I've seen they cut the float, only to increase it later, rinse and repeat.
I need the price to be @ $70 to break even.
Maybe that $0.40 becomes a multiple of RS ratio? 0.40 * 120?
Yeah, we're sitting at about a nickel per share based on where we'd be pre-split with the math being what it is.
I've had mine set to sell off if it hit 40 cents since back in January. I'd love to know why it didn't sell off when it obviously went above 40 cents after the split.
Either they cancel outstanding orders in a split or it is because if you google CNBX instead of CNBXD it still shows the stock at 8 cents and so Etrade has not registered that we are currently in dollars.
Take care, Jim
RE: Chart Inactivity 5-25-22 Did anyone else notice most if not all sites did not have chart activity for Cannabics Wednesday 5-25?
They had the price at $ 6.14 but no open, high, low, etc.
Can anyone explain why?
Thanks, Jim
What are the possible benefits of a reverse stock split at this high ratio?
All I know is I need this to be above 45 to be profitable. And we're a long way from that.
Unless my math is off, the price should be north of $10 per share. The stock’s lost quite a bit of value post split.
Today's VWAP was $8.88. Whoever loaded up this morning must think they know something. Very odd activity. ?????
Does anyone have any opinion on wether or not this stock split will be a good thing?
Break the wall down, build it back up is what I say. crushed lemons make lemonade. They needed at least 1,800,000 to push past phase 2. This was the plan. Don't be upset. Even if it drops. Fuck what do I know..
If nothingness continues, that $3 PS will soon be $0.10 PS. Sad :(
I'm not even looking how many I have left. OTC experience was really eye opening, but good lesson learned.
Holy mother of Christ. My shares disappeared. I have a measly 108 now. grrrrrrrr
Whatchu talkin bout Willis???
On February 14, 2022, our Board of Directors approved a resolution seeking stockholder approval regarding the authorization of the Company’s Board of Directors (the “Board” or the “Board of Directors”) to (i) change the Company’s name from “Cannabics Pharmaceuticals Inc.” to “CNBX Pharmaceuticals Inc.” (the “Name Change”), (ii) effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at any time prior to February 14, 2023, in connection with a potential listing on a NATIONAL STOCK exchange
https://www.sec.gov/Archives/edgar/data/1343009/000168316822001036/cannabics_def14c.htm
CNBX one for 120 reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
It would be nice if this would have some spillover effect on our stock price. Just imagine once our drugs are fully approved by the FDA. KABOOM
I don't think it's related to CNBX but still good news, too bad this didn't come from CNBX.
https://www.benzinga.com/markets/cannabis/22/04/26609834/cannabis-and-pancreatic-cancer-botanical-drug-kills-100-of-cancer-cells-research-on-the-cell-mod
The water seems calm, I wonder what we're all watching.
Looks nice. The historical chart doesn't :D
[LINK] New website is up. Check it out.
https://cnbxpharma.com
The Senate on Thursday unanimously approved a marijuana bill but not the federal legalization measure. it’s a modest bipartisan piece of legislation that’s simply meant to promote research into marijuana.
It would streamline the application process for researchers who want to study the plant and to encourage the Food and Drug Administration (FDA) to develop cannabis-derived medicines.[/color]
I don't post much, if at all, but when I do It's just "data Information"
1.) https://www.marijuanamoment.net/u-s-senate-unanimously-approves-marijuana-reform-bill-on-same-day-that-house-schedules-legalization-vote/
2.) https://www.msn.com/en-us/news/politics/house-poised-to-pass-bill-legalizing-marijuana/ar-AAVBqCf (Enjoy the snacks.)
The Senate on Thursday unanimously approved a marijuana bill but not the federal legalization measure. it’s a modest bipartisan piece of legislation that’s simply meant to promote research into marijuana.
It would streamline the application process for researchers who want to study the plant and to encourage the Food and Drug Administration (FDA) to develop cannabis-derived medicines.[/color]
I don't post much if at all, but when I do It's just "data Information"
1.) https://www.marijuanamoment.net/u-s-senate-unanimously-approves-marijuana-reform-bill-on-same-day-that-house-schedules-legalization-vote/
2.) https://www.msn.com/en-us/news/politics/house-poised-to-pass-bill-legalizing-marijuana/ar-AAVBqCf (Enjoy the snacks.)
I wish this news would translate into a higher share price.
Cannabics Pharmaceuticals Inc. changed to CNBX Pharmaceuticals Inc.:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Hi GoSing,
I got out for a while last year and came back for the traditional end of the year/beginning of the year trends.
I used to stay up to date but haven't as of late. Anything of interest in the pipe? (Puns always intended!!!).
Thanks for your kind words and good to see you as well. Sorry it took me so long to reply.
Take care, Jim
Hi Pierpont,
RE: "1) change name to CNBX Pharmaceuticals - Easier to say, easier to search, easier to find stock symbol"... I have been gone a while. What other name was involved/being considered?
Per your point in # 4, I agree, I came back before the end of the year as I see people sell off to capture their loss and buy back in. I of course hoped for the traditional February bump, but not seeing that this year.
Anything of interest happening?
Take care, Jim
Interesting 8K and S1... so looks like issuing more shares to generate funds AND uplisting.... Now if this all can be done with Positive News/Publicity, perhaps this will be a short term winner like BYRN was last year...
Still here, still invested. Nothing really to do except hold for the long term and hope something positive happens.
1) Agree with the name change
2) Never seen a reverse-split to be beneficial to existing shareholders, as usually the higher price after RS keeps going down.
3) It's a reduction from 100m to 5m, isn't there a rule with big exchanges that require much larger AS than 5m? Maybe I'm just confused.
I am going to remain optimistic here...
1) change name to CNBX Pharmaceuticals - Easier to say, easier to search, easier to find stock symbol
2) 120:1, 80:1, 40:1 reverse split - I think "we" all suspected this would happen at some point. Get above $5 for an up-listing to another exchange, hopefully get the attention of institutional, hedge fund, etc. investors; more likely be able to acquire partner for future testing....
3) Reduction of outstanding shares - Basically to help offset some of the reverse split
4) Historically, Feb-Apr seems to be when this stock moves... for whatever the reasons are...
Having said all of this, does seem like an all or nothing attempt to go to the next level. I am hopeful that CNBX can... and we all finally ride the wave...
I was wondering if there's anyone left here? No response to Proxy and the 10q, did everyone just give up on this?
So a proxy just showed up, wow ok. Someone that knows more please chime in.
In first one they want a name change, but the second one is scary:
the authorization of the Company’s Board of Directors (the “Board” or the “Board of Directors”) to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) in connection with a potential listing on a national stock exchange in a ratio to be determined by the Board based on market conditions and the Company’s trading price at the time of such reverse split in the range of 1:40 to 1:120 at any time prior to February [ ], 2023, whereby every 40-120 (such number of shares, the “Split Denominator”) shares of the authorized, issued and outstanding Common Stock shall be combined into one (1) share of authorized, issued and outstanding Common Stock (the “Reverse Stock Split”); and
3. an amendment to the Company’s Amended and Restated Articles of Incorporation to decrease the number of authorized shares of preferred stock of the Company, par value $0.0001 per share (the “Preferred Stock”), from 100,000,000 to 5,000,000 (the “Preferred Share Decrease”).
There's a 10Q? Does it show revenue?
Followers
|
181
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7485
|
Created
|
11/29/09
|
Type
|
Free
|
Moderators |
Outstanding: 4,966,197
Float: 4,196,841
Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized diagnostic tools, aimed to provide supportive data for practitioners and patients regarding cannabinoid based therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations. Cannabics engages in delivering the maximum amount of supportive data for cancer patients and their doctors, utilizing advanced screening systems and personalized bioinformatics tools.
Cannabics SR' Capsules, Technology Description - Route of administration
There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy.
The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.
The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process. The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.
Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.
Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."
The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.
The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at :
https://clinicaltrials.gov/ct2/show/NCT02359123
"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations," said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.
http://www.cannabics.com/investors
Market Value1 | $72,404,107 | a/o Jan 13, 2017 | |
Authorized Shares | 900,000,000 | a/o Dec 30, 2016 | |
Outstanding Shares | 107,265,344 | a/o Dec 30, 2016 | |
-Restricted | 90,368,887 | a/o Dec 30, 2016 | |
-Unrestricted | 16,896,457 | a/o Dec 30, 2016 | |
Held at DTC | Not Available | ||
Float | 14,295,638 | a/o Jun 30, 2016 | |
Par Value | 0.0001 |
Market Value1 | $37,994,466 | a/o Oct 28, 2016 | |
Authorized Shares | 900,000,000 | a/o Jul 09, 2015 | |
Outstanding Shares | 107,026,665 | a/o Jun 30, 2016 | |
-Restricted | Not Available | ||
-Unrestricted | Not Available | ||
Held at DTC | Not Available | ||
Float | 18,737,071 | a/o Jun 30, 2016 | |
Par Value | 0.0001 |
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |